The medical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 receptor that’s demonstrating significant efficacy in clinical trials for treating obesity. Unlike some available weight loss approaches, retatrutide appears to deliver a significant substantial decrease in body size and benefit metabolic health,